Cutaneous side effects are common with nivolumab treatment, though they are typically self-limited. Here we present a case of persistent lichenoid dermatitis in a patient treated with nivolumab for ...
Lichenoid eruptions have been reported in 0.5%–6% of patients treated with anti-PD-1/PD-L1 immunotherapies. Steroids are the mainstay of treatment for IRAEs. Individuals with grade 1 ICI bullous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results